COVend at Euroanaesthesia 2025 – ARDS in Europe: data and clinical trials
We’re excited to announce that COVend will be featured at Euroanaesthesia 2025 in Lisbon, taking place from 25–27 May. As one of Europe’s leading events for anaesthesia and intensive care professionals, this year’s congress promises to be both dynamic and insightful — and COVend is proud to be part of it.
Interview with Zhiran Wang: Unravelling the Science Behind COVend
The COVend project is dedicated to developing innovative treatments for COVID-19 and its complications. One of the researchers at the heart of this effort is Zhiran Wang, a PhD student at University College Dublin, whose work focuses on understanding vascular damage in COVID-19 patients and the potential of the FX06 drug candidate.
Unlocking the Potential of FX06: An Interview with the UCD Systems Biology Ireland Team on Their Research in COVend
Unlocking the Potential of FX06: An Interview with the UCD Systems Biology Ireland Team on Their Research in COVend Systems Biology Ireland (SBI), University College Dublin (UCD), focuses on developing […]
UCD team presenting COVend research results at the European Congress of Immunology 2024
UCD team presenting COVend research results at the European Congress of Immunology 2024 In September 2024, our partners, Zhiran Wang and Günther Eissner from University College Dublin’s Systems Biology Ireland, […]
COVend featured in the Horizon Europe magazine article “Breathing easier – nature-inspired treatments could relieve acute respiratory distress”
COVend featured in the Horizon Europe magazine article “Breathing easier – nature-inspired treatments could relieve acute respiratory distress” We are thrilled to announce that COVend has been featured in a […]
COVend research presented at 7th European Congress of Immunology in Dublin, 2 September 2024
COVend research presented at 7th European Congress of Immunology in Dublin, 2 September 2024 Our COVend project partner, Zhiran Wang, a researcher from University College Dublin, Systems Biology Ireland, will […]
COVend presented at Euroanaesthesia 2024 Congress in Munich, May 25-27
COVend presented at Euroanaesthesia 2024 Congress in Munich, May 25-27 On May 25-27, COVend participated in the Euroanaesthesia 2024 Congress in Munich, Germany, organised by our partner, the European Society […]
COVend partners at EMBL Conference, EMBO Workshop: Building Networks 2024 in Barcelona, Spain
COVend partners at EMBL Conference, EMBO Workshop: Building Networks 2024 in Barcelona, Spain The EMBL Conference, EMBO Workshop: Building Networks 2024 took place in Barcelona, Spain on May 6-8, bringing […]
Major Milestone Reached: COVend’s IXION 2.0 trial enrols its first patients!
We are excited to announce the start of patient enrollment for the IXION 2.0 clinical trial at the Goethe University Hospital Frankfurt. Due to the evolving dynamics of COVID-19, the project’s focus has shifted to investigating the potential benefits of the FX06 drug for patients with acute respiratory distress syndrome (ARDS). Spearheaded by Prof. Zacharowski and Dr. Petra Wülfroth, the co-founder of F4 Pharma in Vienna, the consortium and clinical trial were restructured in record time, underlining the unwavering joint commitment to innovative medical research in critical health conditions.
Groundbreaking research on Idiopathic Systemic Capillary Leak Syndrome: FX06 is Pioneering New Frontiers in Clarkson Disease Treatment
Our COVend consortium member F4 Pharma’s cooperation partners presented groundbreaking research on Idiopathic Systemic Capillary Leak Syndrome (ISCLS), also known as Clarkson disease, first at the 124° Congresso Nazionale of the Societa Italiana di Medicina Interna (SIMI) in October 2023. Now their paper is officially published in Biomedicine & Pharmacotherapy.
